F S&P 500
5,159.75 +5.00 (+0.10%) F Dow Jones
38,873.00 +41.00 (+0.11%) F Nasdaq
18,003.50 +2.75 (+0.02%) E-mini Russell 2000 Index Futur
2,054.40 +8.60 (+0.42%) Petróleo
78.60 +0.49 (+0.63%) Oro
2,322.50 +13.90 (+0.60%)
Palatin Technologies, Inc. (PTN)
Fuera de horario:
Palatin Technologies, Inc.
Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 34
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, CEO & Director | 979k | N/D | 1962 |
| Mr. Stephen T. Wills CPA, MST | CFO, COO, Executive VP, Treasurer & Secretary | 910.55k | N/D | 1957 |
| Burns McClellan | Vice President of Investor Relations | N/D | N/D | N/D |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer | N/D | N/D | N/D |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer | N/D | N/D | N/D |
| Mr. James E. Hattersley | Senior Vice President of Business Development | N/D | N/D | 1960 |
| Mr. John Dodd Ph.D. | Senior Vice President of Preclinical Development | N/D | N/D | N/D |
| Mr. Robert Jordan | Senior Vice President of Program Operations | N/D | N/D | N/D |
Descripción
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Palatin Technologies, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
